Literature DB >> 27980024

Individualized Tamoxifen Dose Escalation-Letter.

Stijn L W Koolen1, Sander Bins2, Ron H J Mathijssen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27980024     DOI： 10.1158/1078-0432.CCR-16-1967

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  3 in total

1.  Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial.

Authors:  C Louwrens Braal; Anne Kleijburg; Agnes Jager; Stijn L W Koolen; Ron H J Mathijssen; Isaac Corro Ramos; Pim Wetzelaer; Carin A Uyl-de Groot
Journal:  Clin Drug Investig       Date:  2022-01-12       Impact factor: 2.859

2.  Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.

Authors:  C Louwrens Braal; Agnes Jager; Esther Oomen-de Hoop; Justin D Westenberg; Koen M W T Lommen; Peter de Bruijn; Mijntje B Vastbinder; Quirine C van Rossum-Schornagel; Martine F Thijs-Visser; Robbert J van Alphen; Liesbeth E M Struik; Hanneke J M Zuetenhorst; Ron H J Mathijssen; Stijn L W Koolen
Journal:  Clin Pharmacokinet       Date:  2021-11-17       Impact factor: 6.447

3.  Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer.

Authors:  Hye In Woo; Se Kyung Lee; Jiyoung Kim; Seok Won Kim; Jonghan Yu; Soo Youn Bae; Jeong Eon Lee; Seok Jin Nam; Soo-Youn Lee
Journal:  Oncotarget       Date:  2017-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.